Combined small-cell lung carcinoma

Elekta: New Study to Learn From Every Cancer Patient Treated With Magnetic Resonance Radiation Therapy

Retrieved on: 
Monday, February 4, 2019
Health, Medicine, Radiobiology, Medical physics, Radiation therapy, Radioactivity, Treatment of cancer, Therapy, Daniel Przybysz, Combined small-cell lung carcinoma

The study is designed to generate data that enable safe, fast and, above all, 'evidence-based' introduction of magnetic resonance radiation therapy (MR/RT) into clinical practice.

Key Points: 
  • The study is designed to generate data that enable safe, fast and, above all, 'evidence-based' introduction of magnetic resonance radiation therapy (MR/RT) into clinical practice.
  • Information gained through the MOMENTUM study will guide the use of MR/RT to improve outcomes for cancer patients.
  • Radiotherapy is an important component many cancer treatment regimens and approximately 50% of all cancer patients receive radiation during their treatment journey*.
  • "We believe that this kind of rigorous and coordinated approach has tremendous potential to improve patient outcomes and change radiotherapy."

Elekta: New Study to Learn From Every Cancer Patient Treated With Magnetic Resonance Radiation Therapy

Retrieved on: 
Monday, February 4, 2019
Health, Medicine, Radiobiology, Medical physics, Radiation therapy, Radioactivity, Treatment of cancer, Therapy, Daniel Przybysz, Combined small-cell lung carcinoma

The study is designed to generate data that enable safe, fast and, above all, 'evidence-based' introduction of magnetic resonance radiation therapy (MR/RT) into clinical practice.

Key Points: 
  • The study is designed to generate data that enable safe, fast and, above all, 'evidence-based' introduction of magnetic resonance radiation therapy (MR/RT) into clinical practice.
  • Information gained through the MOMENTUM study will guide the use of MR/RT to improve outcomes for cancer patients.
  • Radiotherapy is an important component many cancer treatment regimens and approximately 50% of all cancer patients receive radiation during their treatment journey*.
  • "We believe that this kind of rigorous and coordinated approach has tremendous potential to improve patient outcomes and change radiotherapy."

Analysis Presented at WCLC Highlights Variance Between Oncologists and Expert Recommendations in Intended Immunotherapy Treatment for Advanced NSCLC

Retrieved on: 
Monday, November 19, 2018
Lung cancer, Cancer, Medicine, Clinical medicine, Non-small-cell lung carcinoma, Oncology, Monoclonal antibodies, Cancer treatments, Durvalumab, Combined small-cell lung carcinoma

The treatment for advanced non-small-cell lung cancer (NSCLC) is in the midst of a striking revolution with the advent and expansion of immune checkpoint inhibitors into the current treatment paradigm.

Key Points: 
  • The treatment for advanced non-small-cell lung cancer (NSCLC) is in the midst of a striking revolution with the advent and expansion of immune checkpoint inhibitors into the current treatment paradigm.
  • This makes it challenging for many oncologists to make informed treatment decisions for their patients.
  • "In addition, we found that expert recommendations often changed the intended treatment plan of oncologists, consistent with the potential of this online tool to improve clinical outcomes in patients with advanced NSCLC."
  • Evolving Immunotherapy Practice Patterns in Advanced NSCLC: Analysis of an Online Treatment Decision Tool.

Patients Launch New Study to Shed Light on EGFR-Positive Lung Cancers

Retrieved on: 
Thursday, November 15, 2018
Lung cancer, Cancer, Chemistry, Quinazolines, Organic chemistry, Tyrosine kinase receptors, Amines, Non-small-cell lung carcinoma, Epidermal growth factor receptor, Gefitinib, Combined small-cell lung carcinoma

EGFR gene mutations are commonly found in patients with non-small cell lung cancer, making up 10 to 15 percent of patients in the United States and about 50 percent of young adults with lung cancer.

Key Points: 
  • EGFR gene mutations are commonly found in patients with non-small cell lung cancer, making up 10 to 15 percent of patients in the United States and about 50 percent of young adults with lung cancer.
  • To date, there are no known effective therapies for patients with one rare EGFR mutation (exon 20 insertion).
  • "As a lung cancer patient and a friend of many other lung cancer patients and their families, I know firsthand how heartbreaking it is to develop resistance to treatment.
  • The study, currently open to patients in the U.S. and Canada, is powered by ALCMI's remote study capabilities.

SLLIP Study Meets Primary Endpoint, Finds the Guardant360 Assay Performs Similar to Standard-of-Care Tissue Testing in Advanced NSCLC, Investigators to Report at WCLC

Retrieved on: 
Thursday, September 6, 2018
Medicine, Clinical medicine, Lung cancer, RTT, Biopsy, Non-small-cell lung carcinoma, Cancer, Combined small-cell lung carcinoma

The MedSIR-sponsored SLLIP trial (Spanish Lung Liquid versus Invasive biopsy Program) prospectively enrolled 185 patients with metastatic non-small cell lung cancer.

Key Points: 
  • The MedSIR-sponsored SLLIP trial (Spanish Lung Liquid versus Invasive biopsy Program) prospectively enrolled 185 patients with metastatic non-small cell lung cancer.
  • Each patient was tested with Guardant360 as well as standard-of-care tissue molecular testing ahead of first-line treatment.
  • Throughout the entire cohort, Guardant360 identified a similar number of targets associated with guideline-recommended treatment as tissue did, with Guardant360 finding 47 and tissue finding 48, investigators reported.
  • The SLLIP study is the first of two prospective trials comparing the detection rates of Guardant360 to standard-of-care tissue-based genomic testing in untreated advanced NSCLC.

Immunovia`s Blood-based IMMray™ Biomarker Array Provides Highly Accurate Diagnosis of non-small Cell Lung Cancer in a New Collaborative Study

Retrieved on: 
Thursday, August 9, 2018
RTT, Medicine, Lung cancer, Clinical medicine, Anatomy, Systemic lupus erythematosus, Cancer, Pancreatic cancer, Non-small-cell lung carcinoma, Biomarker, Combined small-cell lung carcinoma

Accounting for nearly 14% of all new cancers, NSCLC is one of the top three cancer types by incidence and number one by mortality.

Key Points: 
  • Accounting for nearly 14% of all new cancers, NSCLC is one of the top three cancer types by incidence and number one by mortality.
  • The study included 100 serum samples - 50 NSCLC and 50 controls - and was performed to assess the technical performance of the IMMray platform in lung cancer.
  • The company is now performing clinical validation studies for the commercialization of IMMray PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer.
  • The first test from this program, IMMray SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation.

PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018

Retrieved on: 
Monday, June 4, 2018
Cancer, Lung cancer, Clinical medicine, Small-cell carcinoma, Combined small-cell lung carcinoma, Durvalumab

The multicenter, phase II trial is assessing the safety and efficacy of lurbinectedin in different solid tumors.

Key Points: 
  • The multicenter, phase II trial is assessing the safety and efficacy of lurbinectedin in different solid tumors.
  • Among these, small-cell lung cancer, recurrent after one chemotherapy prior line, began by recruiting 15 patients, and later increased to 100 after observing 5 responses in the first 15 patients.
  • PharmaMar will present the results of the 61 evaluated patients out of the 72 patients recruited so far in the abstract titled "Efficacy and safety of lurbinectedin (PM1183, Zepsyre) in small-cell lung cancer (SCLC): results from a phase 2 study" (abstract#8570).
  • "The patients included in this study with small-cell lung cancer are responding favorably to the treatment with lurbinectedin as a single agent.

PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018

Retrieved on: 
Monday, June 4, 2018
Cancer, Lung cancer, Clinical medicine, Small-cell carcinoma, Combined small-cell lung carcinoma, Durvalumab

The multicenter, phase II trial is assessing the safety and efficacy of lurbinectedin in different solid tumors.

Key Points: 
  • The multicenter, phase II trial is assessing the safety and efficacy of lurbinectedin in different solid tumors.
  • Among these, small-cell lung cancer, recurrent after one chemotherapy prior line, began by recruiting 15 patients, and later increased to 100 after observing 5 responses in the first 15 patients.
  • PharmaMar will present the results of the 61 evaluated patients out of the 72 patients recruited so far in the abstract titled "Efficacy and safety of lurbinectedin (PM1183, Zepsyre) in small-cell lung cancer (SCLC): results from a phase 2 study" (abstract#8570).
  • "The patients included in this study with small-cell lung cancer are responding favorably to the treatment with lurbinectedin as a single agent.

Global Non-Small Cell Lung Cancer Epidemiology and Patient Flow Analysis 2017-2026

Retrieved on: 
Tuesday, April 17, 2018
Lung cancer, Cancer, Small-cell carcinoma, Epidemiology of cancer, Non-small-cell lung carcinoma, Treatment of cancer, Adenocarcinoma of the lung, Combined small-cell lung carcinoma

The "Global Non-Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Non-Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering.
  • The research provides insights into Non-Small Cell Lung Cancer epidemiology, Non-Small Cell Lung Cancer diagnosed patients, and Non-Small Cell Lung Cancer treatment rate for US, Japan, and EU5 countries.
  • The research measures key indicators including prevalence of Non-Small Cell Lung Cancer derived from epidemiological analysis, patients diagnosed with Non-Small Cell Lung Cancer, and patients treated with a drug therapy.
  • The research provides estimates and forecasts of Non-Small Cell Lung Cancer prevalence, Non-Small Cell Lung Cancer diagnosis rate, and Non-Small Cell Lung Cancer treatment rate for the period 2017 - 2026.